{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:28:58Z","timestamp":1792301338541,"version":"4.4.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2017,9,12]],"date-time":"2017-09-12T00:00:00Z","timestamp":1505174400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s40265-017-0812-3","type":"journal-article","created":{"date-parts":[[2017,9,12]],"date-time":"2017-09-12T09:35:11Z","timestamp":1505208911000},"page":"1665-1675","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Ulipristal Acetate: A Review in Symptomatic Uterine Fibroids"],"prefix":"10.1007","volume":"77","author":[{"given":"Karly P.","family":"Garnock-Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean T.","family":"Duggan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,12]]},"reference":[{"issue":"1","key":"812_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007995.2014.982246","volume":"31","author":"SS Singh","year":"2015","unstructured":"Singh SS, Belland L. Contemporary management of uterine fibroids: focus on emerging medical treatments. Curr Med Res Opin. 2015;31(1):1\u201312.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"812_CR2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejogrb.2010.07.016","volume":"152","author":"H Marret","year":"2010","unstructured":"Marret H, Fauconnier A, Chabbert-Buffet N, et al. Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause. Eur J Obstet Gynecol Reprod Biol. 2010;152(2):133\u20137.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"812_CR3","unstructured":"National Institute for Health and Care Excellence. Heavy menstrual bleeding: assessment and management. Clinical guideline cg44. 2016. http:\/\/www.nice.org.uk . Accessed 5 Apr 2017."},{"issue":"8","key":"812_CR4","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2165\/11209400-000000000-00000","volume":"72","author":"JD Croxtall","year":"2012","unstructured":"Croxtall JD. Ulipristal acetate: in uterine fibroids. Drugs. 2012;72(8):1075\u201385.","journal-title":"Drugs."},{"key":"812_CR5","unstructured":"European Medicines Agency. Esmya\u00ae (ulipristal acetate 5\u00a0mg tablets): EU summary of product characteristics. 2016. http:\/\/www.ema.europa.eu\/ . Accessed 15 Mar 2017."},{"key":"812_CR6","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejogrb.2015.05.022","volume":"191","author":"BS Yun","year":"2015","unstructured":"Yun BS, Seong SJ, Cha DH, et al. Changes in proliferating and apoptotic markers of leiomyoma following treatment with a selective progesterone receptor modulator or gonadotropin-releasing hormone agonist. Eur J Obstet Gynecol Reprod Biol. 2015;191:62\u20137.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"812_CR7","doi-asserted-by":"crossref","unstructured":"Horak P, Mara M, Dundr P, et al. Effect of a selective progesterone receptor modulator on induction of apoptosis in uterine fibroids in vivo. Int J Endocrinol. 2012;2012:436174.","DOI":"10.1155\/2012\/436174"},{"issue":"1 Suppl","key":"812_CR8","first-page":"88A","volume":"22","author":"J Cox","year":"2015","unstructured":"Cox J, Malik M, Britten-Webb J, et al. Ulipristal acetate inhibits extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized controlled trial [abstract]. Reprod Sci. 2015;22(1 Suppl):88A.","journal-title":"Reprod Sci."},{"key":"812_CR9","doi-asserted-by":"crossref","unstructured":"Courtoy GE, Donnez J, Marbaix E, et al. In vivo mechanisms of uterine fibroid volume reduction with ulipristal acetate treatment [abstract no. ES25-0451]. Gynecol Surg. 2016;13(Suppl 1):S69.","DOI":"10.1016\/j.fertnstert.2015.04.025"},{"key":"812_CR10","doi-asserted-by":"crossref","unstructured":"Courtoy GE, Donnez J, Marbaix E, et al. In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment. Fertil Steril. 2015;104(2):426\u201334.e1.","DOI":"10.1016\/j.fertnstert.2015.04.025"},{"issue":"3 Suppl","key":"812_CR11","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1016\/j.fertnstert.2016.07.806","volume":"106","author":"M Malik","year":"2016","unstructured":"Malik M, Britten JL, Cox J, et al. Cytokine regulation central to ulipristal mediated leiomyoma treatment [abstract no. P-466]. Fertil Steril. 2016;106(3 Suppl):e280.","journal-title":"Fertil Steril"},{"issue":"3","key":"812_CR12","first-page":"531","volume":"32","author":"LHR Whitaker","year":"2017","unstructured":"Whitaker LHR, Murray AA, Matthews R, et al. Selective progesterone receptor modulator (SPRM) ulipristal acetate (UPA) and its effects on the human endometrium. Hum Reprod. 2017;32(3):531\u201343.","journal-title":"Hum Reprod"},{"issue":"6","key":"812_CR13","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/PGP.0b013e318251035b","volume":"31","author":"AR Williams","year":"2012","unstructured":"Williams AR, Bergeron C, Barlow DH, et al. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Int J Gynecol Pathol. 2012;31(6):556\u201369.","journal-title":"Int J Gynecol Pathol"},{"issue":"11","key":"812_CR14","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1210\/jc.2008-0731","volume":"93","author":"S Ravet","year":"2008","unstructured":"Ravet S, Munaut C, Blacher S, et al. Persistence of an intact endometrial matrix and vessels structure in women exposed to VA-2914, a selective progesterone receptor modulator. J Clin Endocrinol Metab. 2008;93(11):4525\u201331.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"812_CR15","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1210\/jc.2006-2816","volume":"92","author":"N Chabbert-Buffet","year":"2007","unstructured":"Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2007;92(9):3582\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"812_CR16","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/jcpt.12098","volume":"38","author":"O Pohl","year":"2013","unstructured":"Pohl O, Osterloh I, Gotteland JP. Effects of erythromycin at steady-state concentrations on the pharmacokinetics of ulipristal acetate. J Clin Pharm Ther. 2013;38(6):512\u20137.","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"812_CR17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5414\/CP201789","volume":"51","author":"O Pohl","year":"2013","unstructured":"Pohl O, Osterloh I, Lecomte V, et al. Changes in gastric pH and in pharmacokinetics of ulipristal acetate: a drug-drug interaction study using the proton pump inhibitor esomeprazole. Int J Clin Pharmacol Ther. 2013;51(1):26\u201333.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"5","key":"812_CR18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJMoa1103182","volume":"366","author":"J Donnez","year":"2012","unstructured":"Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366(5):409\u201320.","journal-title":"N Engl J Med"},{"issue":"5","key":"812_CR19","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa1103180","volume":"366","author":"J Donnez","year":"2012","unstructured":"Donnez J, Tomaszewski J, Vazquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012;366(5):421\u201332.","journal-title":"N Engl J Med"},{"key":"812_CR20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejogrb.2016.11.003","volume":"208","author":"H Fernandez","year":"2017","unstructured":"Fernandez H, Schmidt T, Powell M, et al. Real world data of 1473 patients treated with ulipristal acetate for uterine fibroids: Premya study results. Eur J Obstet Gynecol Reprod Biol. 2017;208:91\u20136.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"5","key":"812_CR21","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.fertnstert.2016.06.012","volume":"106","author":"A Murji","year":"2016","unstructured":"Murji A, Crosier R, Chow T, et al. Role of ethnicity in treating uterine fibroids with ulipristal acetate. Fertil Steril. 2016;106(5):1165\u20139.","journal-title":"Fertil Steril"},{"key":"812_CR22","doi-asserted-by":"crossref","unstructured":"Donnez J, Vazquez F, Tomaszewski J, et al. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril. 2014;101(6):1565\u201373.e1-18.","DOI":"10.1016\/j.fertnstert.2014.02.008"},{"key":"812_CR23","doi-asserted-by":"crossref","unstructured":"Donnez J, Hudecek R, Donnez O, et al. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril. 2015;103(2):519\u201327.e3.","DOI":"10.1016\/j.fertnstert.2014.10.038"},{"key":"812_CR24","doi-asserted-by":"crossref","unstructured":"Donnez J, Donnez O, Matule D, et al. Long-term medical management of uterine fibroids with ulipristal acetate. Fertil Steril. 2016;105(1):165\u201373.e4.","DOI":"10.1016\/j.fertnstert.2015.09.032"},{"issue":"3","key":"812_CR25","doi-asserted-by":"crossref","first-page":"e0173523","DOI":"10.1371\/journal.pone.0173523","volume":"12","author":"BC Fauser","year":"2017","unstructured":"Fauser BC, Donnez J, Bouchard P, et al. Safety after extended repeated use of ulipristal acetate for uterine fibroids. PLoS ONE. 2017;12(3):e0173523.","journal-title":"PLoS ONE"},{"key":"812_CR26","unstructured":"European Medicines Agency. European public assessment report (EPAR) for Esmya. 2015. http:\/\/www.ema.europa.eu . Accessed 17 Aug 2017."},{"key":"812_CR27","doi-asserted-by":"crossref","unstructured":"Raga F, Moscardo I, Cholvi S, et al. Does ulipristal acetate administration for symptomatic uterine fibroids impact ovarian reserve? [abstract]. In: 32nd Annual Meeting of the European Society of Human Reproduction and Embryology. 2016.","DOI":"10.26226\/morressier.573c1514d462b80296c98d7a"},{"issue":"Suppl 1","key":"812_CR28","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/S0049-3848(17)30072-5","volume":"151","author":"J Davies","year":"2017","unstructured":"Davies J, Kadir RA. Heavy menstrual bleeding: an update on management. Thromb Res. 2017;151(Suppl 1):S70\u20137.","journal-title":"Thromb Res"},{"key":"812_CR29","doi-asserted-by":"crossref","unstructured":"Perez-Lopez FR, Ornat L, Ceausu I, et al. EMAS position statement: management of uterine fibroids. Maturitas. 2014;79(1):106-16.","DOI":"10.1016\/j.maturitas.2014.06.002"},{"issue":"6","key":"812_CR30","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/uog.14668","volume":"45","author":"P Czuczwar","year":"2015","unstructured":"Czuczwar P, Wozniak S, Szkodziak P, et al. Influence of ulipristal acetate therapy compared with uterine artery embolization on fibroid volume and vascularity indices assessed by three-dimensional ultrasound: prospective observational study. Ultrasound Obstetr Gynecol. 2015;45(6):744\u201350.","journal-title":"Ultrasound Obstetr Gynecol"},{"key":"812_CR31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejogrb.2015.06.018","volume":"192","author":"N Bizzarri","year":"2015","unstructured":"Bizzarri N, Ghirardi V, Remorgida V, et al. Three-month treatment with triptorelin, letrozole and ulipristal acetate before hysteroscopic resection of uterine myomas: prospective comparative pilot study. Eur J Obstet Gynecol Reprod Biol. 2015;192:22\u20136.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"5","key":"812_CR32","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.fertnstert.2014.07.1253","volume":"102","author":"M Luyckx","year":"2014","unstructured":"Luyckx M, Squifflet J-L, Jadoul P, et al. First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids. Fertil Steril. 2014;102(5):1404\u20139.","journal-title":"Fertil Steril"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-017-0812-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0812-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0812-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T13:23:17Z","timestamp":1602940997000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-017-0812-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,12]]},"references-count":32,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["812"],"URL":"https:\/\/doi.org\/10.1007\/s40265-017-0812-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,12]]}}}